MEND: Funding, Investors & Team (Sep 2026)
MEND is a company focused on life sciences, determined to assist individuals in achieving better health through healing. The company's focus is on developing personalized medical food interventions and clinical nutrition to improve outcomes for patients dealing with injury or surgery, those who are aging, and those who engage in physical activities. MEND has garnered interest from many hospitals, healthcare systems, professional sports teams in all major leagues, and the top forces within the US Military.
MEND has raised $47.0M across 4 funding rounds on record, the most recent a Series A of $20.0M announced in Dec 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
MEND Company Profile and Key Stats
Latest funding round on record: Dec 2025.
MEND Funding Rounds
MEND raised $10.5M in an undisclosed round announced in Apr 2023.
2 months later, a Series A of $15.0M was announced in Jun 2023.
2 years later, an undisclosed round of $1.5M was announced in Jun 2025.
6 months later, a Series A of $20.0M was announced in Dec 2025.
MEND Founders and Leadership Team
Contact details for the MEND team: 1 of 2 have an email address on file.
Start 14-day free trial →MEND Funding Compared to Other Biotechnology Startups
MEND's latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like MEND in Biotechnology and New York
Companies Similar to MEND
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
MEND Funding FAQs
What does MEND do?
MEND is a company focused on life sciences, determined to assist individuals in achieving better health through healing. The company's focus is on developing personalized medical food interventions and clinical nutrition to improve outcomes for patients dealing with injury or surgery, those who are aging, and those who engage in physical activities. MEND has garnered interest from many hospitals, healthcare systems, professional sports teams in all major leagues, and the top forces within the US Military.
How much funding has MEND raised?
MEND has raised $47.0M across 4 rounds on record. The most recent is a Series A of $20.0M announced in Dec 2025.
When did MEND last raise funding?
MEND's most recent funding round on record is a Series A of $20.0M, announced in Dec 2025.
Who founded MEND?
FundedIQ lists Eziah Syed (Founder), J Whitney Stevens (Founder) at MEND.
Where is MEND headquartered?
MEND is based in New York, United States.
How many employees does MEND have?
MEND is in the 11-50 employee band.
How does MEND's funding compare to other Biotechnology startups?
MEND's latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's MEND Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MEND is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.